Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4833 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 |
filingDate |
2010-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2017-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2017-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-101791404-B1 |
titleOfInvention |
Pharmaceutical dosage form for oral administration of a Bcl-2 family inhibitor |
abstract |
The present invention relates to a process for the preparation of N- (4- (4 - ((2- (4-chlorophenyl) -5,5-dimethyl-1-cyclohex- Benzyl) -4 - ((1 R) -3- (morpholin-4-yl) -1 - ((phenylsulfanyl) methyl) Solvate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizing agent, in the manufacture of a medicament. The invention further relates to a process for the manufacture of said pharmaceutical dosage forms and the use of said dosage form for the treatment of proliferative disorders. |
priorityDate |
2009-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |